Earlier in the year, the United States Supreme Court decided to hear a case regarding the country’s drug industry and federal antitrust enforcers, a billion dollar case that has turned ugly. The outcome of this said case will decide on how fast cheaper generic drugs can be released in the market. The judges explained that they will be making one Abbott Laboratories case as their basis on how to deal with the “pay for delay” agreement which has drug buyers spending a total of $3.5 billion per year.
The agreement’s terms include having branded drug manufacturers pay a sum to other companies to discontinue selling generic versions of their products. This, as the pharmaceutical industry puts it, is a licit settlement of patent dispute. Deals like these have been made way back since 2005, and as the Federal Trade Commission is currently trying to suppress the matter, several companies – Bayer AG (BAYN), Merck & Co. (MRK), Bristol-Myers Squibb Co. (BMY), Watson Pharmaceuticals Inc. (WPI) and Teva Pharmaceutical Industries Ltd. (TEVA) – have been the center of many court cases.
These settlements, which are also termed as reverse payments, are generally acceptable in the opinion of three federal appeals courts that would later rule on the matter in June. Antitrust enforcers and drug manufacturers want the Supreme Court to set a standard that will apply to all states. Ralph Neas, the president for the Generic Pharmaceutical Association in Washington, says that “This case could determine how an entire industry does business because it would dramatically affect the economics of each decision to introduce a generic drug.”
With the help of the Justice Department, the Federal Trade Commission, is filing an appeal to reverse a ruling relating to an Androgel (a drug indicated for decreased testosterone levels) lawsuit against Solvay Pharmaceuticals Inc. (now controlled by Abbot Labs), along with three generic drug companies. Solvay had predicted a significant decrease in profits once competition would arrive, and so they paid off three generic drug manufacturers $42 million per year just to postpone the release of rival drugs.
This happened after the Food and Drug Administration approved to have generic versions in the market. However, there was no confirmation that a rival generic drug is scheduled for immediate release.“ The agreements made economic sense only as a mechanism for Solvay to pay its nascent generic competitors to delay competing with it,” according to the FTC.